Recipient: Professor Brandon Wainwright
Institute: University of Queensland
Funding: $196,207 July 2019 to June 2022
Funding partner: This project is supported by The Kids' Cancer Project 2019 Power Pledge donors
The Wainwright laboratory has identified a promising new drug to treat the most frequent brain tumour in children.

Brain tumours are the leading cause of cancer related death and disability in children. The most common of these is medulloblastoma, a tumour arising in the cerebellum, and it is associated with very poor survival.
Using functional genomics and bioinformatics the Wainwright lab searched for potential new therapeutics for the disease and discovered CDK4/6, a new drug with a lot of potential.
In this latest research study, the team will test it in combination with chemotherapy and radiotherapy in the lab. If successful, it promises to improve survival. In the longer term, it may also be able to reduce the dose of toxic chemotherapy and radiation therapy, therefore significantly improving quality of life for survivors.
Results will determine how this drug can be effectively incorporated into existing treatment and will provide the evidence needed to justify a new children’s brain cancer clinical trial.

This project recieved further support through Cancer Australia's Priority-driven Collaborative Cancer Research Scheme.
Science is the solution for kids with cancer
The only way to improve outcomes for children diagnosed with cancer is through advances in medical research. Every day and every donation takes us closer to a cure.
Select your donation details
Please enter the amount you would like to donate

The Kids' Cancer Project is an ACNC Registered Charity 
ABN 13 061 138 181 | CFN 10581